Clinical trial · Interventional
Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy
Lung Perfusion PET / CT Using Gallium68-MMA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy
NCT04942275CI-TRIAL-00060933PEGASUSunknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective study evaluating the feasibility of treatment planning integrating lung perfusion PET/CT using Ga68-MAA to preserve functional lung areas during stereotactic body radiation therapy (SBRT).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Metastasis | Lung Neoplasm | PROBABILISTIC | 0.70 |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| SBRT | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pre-therapeutic imaging test | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention : Lung perfusion PET/CT using Ga68-MAA and SBRT planification
- description
- All patients included for treatment with stereotactic radiotherapy for non-small cell lung cancer or lung metastasis will benefit from a pre-therapeutic functional assessment including: * The standard functional assessment recommended before performing an SBRT. * A perfusion PET/CT scan The treatment planning will be carried out in 2 stages: * First, an anatomical planning will be carried out, blinded to the PET results. * Then, a functional planning, respecting the standard constraints applied during anatomical planning, but also incorporating a new "functional lung volume" constraint defined by pulmonary PET, will then be carried out. A follow-up will be carried out for 12 months, including repeated perfusion PET/CT imaging at 3 and 12 months
- interventionNames
- Drug: Pre-therapeutic imaging test
Primary outcomes (1)
- measure
- Patients with a dose reduction to the functional lung (estimated during functional planning).
- timeFrame
- Baseline, one week after lung perfusion PET / CT scan using Ga68-MAA
- description
- Percentage of patients for whom it is possible to reduce the dose to the functional lung (estimated during the functional planning). A reduction in the dose to the functional lung will be defined by: * A decrease of at least 5% in functional lung volume included in V20Gy. or * A decrease of at least 5% in total relative lung function included in the V20G.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years * Insured patient * Patient treated at the Brest CHRU for SBRT of a primary or secondary pulmonary lesion Exclusion Criteria: * Unable/unwilling to give informed consent * Pregnancy / breast-feeding patient * Patient under guardianship or curatorship * Patient with contraindication to the administration of macroaggregates of human albumin
References
Publications (1)
- DERIVEDLe Roux PY, Le Pennec R, Bourbonne V, Blanc-Beguin F, Pavoine M, Kerleguer K, Mauguen M, Pradier O, Salaun PY, Lucia F, Bourhis D. Pulmonary uptake value (PUV): a new quantification method for lung PET/CT imaging. EJNMMI Res. 2025 Jul 1;15(1):79. doi: 10.1186/s13550-025-01274-y. PMID 40591115